Clinical observation of neutralizing antibody DXP‐604 for treatment critical COVID‐19 patients infected with SARS‐CoV‐2 Delta variant
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Medical Virology"
DOI: 10.1002/jmv.28742
Abstract: From January to March 2022, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Delta (B.1.617.2) infection was prevalent in Yuzhou and Zhengzhou. DXP‐604 is a broad‐spectrum antiviral monoclonal antibody, which has excellent viral neutralization ability in… read more here.
Keywords: dxp 604; cov delta; neutralizing antibody; treatment ... See more keywords